Follow

Submissions from 2023

Link

O-serotype Distribution of Escherichia Coli Causing Invasive Disease in Tertiary Care Hospital Patients, Jeroen Geurtsen, Joachim Doua, Luis Martinez-Martinez, Patricia I. de Palacios, Jeff Powis, Matthew Sims, Peter Hermans, Oliver Barraud, Philippe Lanotte, Joshua T. Thaden, Oscar Go, Bart Spiessens, Darren Abbanat, Florian Wagenlehner, Tetsuya Matsumoto, Marc Bonten, Michal Sarnecki, and Jan Poolman

Link

The Impact of Age on Microbiome Diversity and Engraftment of Fecal Microbiota Spores, Live (FMS) in Patients With Recurrent Clostridioides difficile Infection, Anne J. Gonzales-Luna, Kevin D. Litcofsky, Timothy J. Straub, Dina Hot, Brooke Hassan, Matthew Sims, Jennifer R. Wortman, Matthew R. Hen, and Barbara McGovern

Link

Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides Difficile Infection (rCDI), Anne J. Gonzales-Luna, Kevin Litcofsky, Tim Straub, Dina Hot, Barbara McGovern, Brooke Hasson, Matthew Sims, Christopher Ford, and Matthew Henn

Link

Social Determinants of Health in Extended Spectrum Beta-Lactamase Carriage in the Urine - The Influence of Race, Ethnicity and Sex in the Outpatient Setting, Jenna Herkness and Matthew Sims

Link

Understanding the Barriers to Sexual Health in Middle Eastern Immigrant Women, Noora Kazanji, Hana Masri, and Laura Power

Link

Low Birthweight and Retention in HIV Care Among Postpartum Women Living With HIV in Ghana, Noora Kazanji, Kwame Sakyi, and Bianca Edler

Link

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection, Matthew Sims, Michael Silverman, Thomas Louie, Elaine Wang, Colleen Kraft, Mayur Ramesh, Tatiana Bogdanovich, Kelly Brady, David Lombardi, and Asli Memisoglu

Submissions from 2022

Incidence of hospitalizations in ECOSPOR III, a phase 3, double-blind, randomized trial in patients with recurrent clostridioides difficile infection., A Amin, M Sims, C Berenson, E Wang, S Pham, and S Huang

Developing accurate prognostics for sepsis, Alexandra I. Halalau, Francisco R. Davila, Hugo Davila-Grijalva, and Matthew D. Sims

PDF

Clinical Pathways Leading to Antibiotic Initiation in Patients with Suspected Infection and Their Association with Delays and Mortality, X Han, C Lopez-Espina, P A. Verhoef, A Spicer, A Bhargava, L Schmalz, Matthew Sims, Alexandra Halalau, Nicholas Maddens, and Aimee Espinosa

Link

Procalcitonin and D-dimer levels at baseline, but not CRP, were informative of COVID-19 hospitalization outcomes, Trini Mathew, Julie George, Christine N. Yost, Mustafa Deebajah, Paul C. Johnson, James Huang, and Christopher F. Carpenter

PDF

Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides Difficile Infection (CDI) Compared to Placebo, Regardless of Presence or Absence of Comorbidities Including Chronic Obstructive Disease (COPD) and Asthma, BH McGovern, T Louie, S Cohen, M Sims, E Wang, H Wu, K Brady, and L von Moltke

PDF

Combining DRIP Score and Rapid Diagnostics for Improved Antibiotic Stewardship, Richard Ramirez and Matthew Sims

PDF

SARS-CoV-2 Immunization/Therapeutics, Matthew Sims

Link

Vaccine Hesitancy Among Healthcare Providers, Matthew Sims

Submissions from 2021

Link

Investigational Microbiome Therapeutic SER-109 Reduces Recurrence of Clostridioides Difficile Infection (CDI) Compared to Placebo, Regardless of Risk Factors for Recurrence, Stuart H. Cohen, Thomas J. Louie, Matthew D. Sims, John Pullman, Elaine E. Wang, and Henry Wu

PDF

Cost-Effectiveness Analysis of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Immunocompromised Adults Diagnosed with Select Cancers in the United States, Desmond Curran, Brandon Patterson, Justin Carrico, Ahmed Salem, Elizabeth La, Stephane Lorenc, Katherine Hicks, Sara Poston, and Christopher Carpenter

PDF

Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States, Desmond Curran, Ahmed Salem, Stephane Lorenc, Brandon Patterson, Justin Carrico, Katherine A. Hicks, Elizabeth M. La, Sara Poston, and Christopher F. Carpenter

Link

COVID-19 Seropositivity and Asymptomatic Rates in Healthcare Workers at Beaumont, Hans Keil and Matthew D. Sims

Link

Time to Recurrence of Clostridioides Difficile Infection (rCDI) is Rapid Following Completion of Standard of Care Antibiotics: Results from ECOSPOR-III, a Phase 3 Double-Blind, Placebo-Controlled Randomized Trial of SER-109, an Investigational Microbiome Therapeutic, Thomas J. Louic, Matthew D. Sims, Richard Nathan, Steven O'Marro, Princy N. Kumar, Elain E. Wang, and Robert Stevens

PDF

Current Challenges in COVID-19 Triaging: A Global Perspective, Mauli Patel, Robin Sudandiradas, Trini Mathew, Paul Kilgore, Mahadev Rao, Chiranjay Mukhopadhay, and Marcus Zervos

Link

Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy With Meropenem, Jason M. Pogue, Michael J. Rybak, Kyle Stamper, Dror Marchaim, Visanu Thamlikitkul, Yehuda Carmeli, and Matthew D. Sims

Link

The Impact of In Vitro Synergy Between Colistin and Meropenem on Clinical Outcomes in Invasive Carbapenem-Resistant Gram-Negative Infections: A Report From the OVERCOME Trial, Jason M. Pogue, Michael J. Rybak, Kyle Stamper, Dror Marchaim, Visanu Thamlikitkul, Yehuda Carmeli, and Matthew D. Sims

Infectious Diseases Research at Beaumont with a Focus on COVID-19, Matthew D. Sims

Link

Kinks and Quirks of Research During A Pandemic., Matthew D. Sims

Link

SARS-CoV-2 Virology and Immunization, Matthew D. Sims

Link

Diagnostic Testing Among Patients With Suspected Recurrent Clostridioides Difficile Infection (rCDI) in ECOSPOR-III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials, Matthew D. Sims, Sahil Khanna, Darrell Pardi, Paul Feuerstadt, Charles Berenson, Henry Wu, and Elaine E. Wang

Link

SER-109, an Investigational Microbiome Therpeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides Difficile Infection (rCDI) After Standard-of-Care Antibiotics, Timothy J. Straub, Liyang Diao, Christopher Ford, Matthew D. Sims, Thomas J. Louie, Charles Berenson, and Colleen S. Kraft

Submissions from 2019

Link

The Emperor's New Clothes: Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE)., Matthew Sims

Submissions from 2017

Link

Mycoplasma genitalium Prevalence and Variability Based on Gender, Race and Sexual Preference in Patients Attending the Oakland County Health Department Disease Clinic, Valida Bajrovic and Paul Chittick

Link

Outcome Based Study of Carbapenem Use Relative to ESBLs (OBSCURE), Otavio Pereira Rodrigues and Matthew Sims

Link

Doing the Same with Less: A Randomized, Multinational, Open-Label, Adjudicator-Blinded Trial of an Algorithm vs. Standard of Care to Determine Treatment Duration for Staphylococcal Bacteremia, Matthew Sims

Link

Potential Impact of Rapid Diagnostics in Management of Suspected Pneumonia, Matthew Sims